SUPN
Supernus Pharmaceuticals, Inc.Healthcare · $2.4B market cap
Verdict
Share price
$42.38
close of Oct 3, 2026
Fair value
$34.76
Sticker Price
Payback Price
$13.90
buy price
SUPN is Overpriced: at $42.38 it trades 22% above its fair value of $34.76. Its buy price (Payback Price) is $13.90, 67% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.
How we valued it
Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow SUPN
Get notified when it reaches its buy price of $13.90. Free.
Create a free accountSuperinvestors
1 of the investors we track holds SUPN. In Q1 2026, 1 trimmed. Who we track
Moves in Q1 2026
Trimmed: Third Avenue Management
Insider activity
Since Jul 29, 2026: no open-market purchases and 15 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
DEC TIMOTHY C
Senior Vice-President & CFO · 2026-08-12
Tax withholding
$28K
DEC TIMOTHY C
Senior Vice-President & CFO · 2026-08-12
Option exercise
1,250 shares
Mottola Frank
SVP, Chief Tech. Ops. Officer · 2026-08-12
Tax withholding
$37K
Mottola Frank
SVP, Chief Tech. Ops. Officer · 2026-08-12
Option exercise
1,650 shares
Bhatt Padmanabh P.
Sr. VP of IP, CSO · 2026-08-12
Tax withholding
$54K
Show all 15 other filingsShow fewer
Bhatt Padmanabh P.
Sr. VP of IP, CSO · 2026-08-12
Option exercise
2,500 shares
Rubin Jonathan
SVP, Chief Medical Officer · 2026-08-12
Tax withholding
$17K
Rubin Jonathan
SVP, Chief Medical Officer · 2026-08-12
Option exercise
750 shares
Khattar Jack A.
President, CEO · 2026-08-12
Tax withholding
$589K
Khattar Jack A.
President, CEO · 2026-08-12
Option exercise
29,849 shares
Rubin Jonathan
SVP, Chief Medical Officer · 2026-07-29
Award
750 shares
Bhatt Padmanabh P.
Sr. VP of IP, CSO · 2026-07-29
Award
2,500 shares
Mottola Frank
SVP, Chief Tech. Ops. Officer · 2026-07-29
Award
1,650 shares
DEC TIMOTHY C
Senior Vice-President & CFO · 2026-07-29
Award
1,250 shares
Khattar Jack A.
President, CEO · 2026-07-29
Award
29,849 shares
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works